Akeso, Inc. Logo

Akeso, Inc.

9926.HK

(0.8)
Stock Price

67,95 HKD

22.89% ROA

39.49% ROE

25.6x PER

Market Cap.

53.597.290.835,20 HKD

63.74% DER

0% Yield

44.81% NPM

Akeso, Inc. Stock Analysis

Akeso, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Akeso, Inc. Fundamental Stock Analysis
# Analysis Rating
1 Assets Growth

This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.

2 DER

The stock has a reasonable amount of debt compared to its ownership (71%), suggesting a balanced financial position and a moderate level of risk.

3 ROE

Negative ROE (-40.1%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

4 ROA

The stock's ROA (-21.79%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

5 PBV

The stock's high Price-to-Book Value (P/BV) ratio (13.54x) suggests it's overvalued, potentially making it an expensive investment.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

8 Graham Number

The company's Graham number suggests that its stock price is overestimated, implying that it may not be a promising investment opportunity.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (-54), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Akeso, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Akeso, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Akeso, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Akeso, Inc. Revenue
Year Revenue Growth
2018 2.826.000
2019 70.879.000 96.01%
2019 70.879.000 0%
2020 0 0%
2021 225.626.000 100%
2022 837.656.000 73.06%
2023 3.397.576.000 75.35%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Akeso, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2018 161.095.000
2019 308.388.000 47.76%
2019 308.388.000 0%
2020 768.589.000 59.88%
2021 1.122.957.000 31.56%
2022 1.323.098.000 15.13%
2023 2.717.408.000 51.31%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Akeso, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2018 6.759.000
2019 31.176.000 78.32%
2019 55.421.000 43.75%
2020 253.029.000 78.1%
2021 243.517.000 -3.91%
2022 199.007.000 -22.37%
2023 398.660.000 50.08%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Akeso, Inc. EBITDA
Year EBITDA Growth
2018 -140.991.000
2019 -313.158.000 54.98%
2019 -279.517.000 -12.04%
2020 -1.008.003.000 72.27%
2021 -1.316.319.000 23.42%
2022 -1.445.849.000 8.96%
2023 -1.952.212.000 25.94%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Akeso, Inc. Gross Profit
Year Gross Profit Growth
2018 2.826.000
2019 70.879.000 96.01%
2019 70.879.000 0%
2020 -1.903.000 3824.59%
2021 195.409.000 100.97%
2022 734.542.000 73.4%
2023 3.161.972.000 76.77%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Akeso, Inc. Net Profit
Year Net Profit Growth
2018 -140.053.000
2019 -352.190.000 60.23%
2019 -281.762.000 -25%
2020 -1.036.374.000 72.81%
2021 -1.074.933.000 3.59%
2022 -1.168.393.000 8%
2023 -1.986.980.000 41.2%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Akeso, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2018 0
2019 0 0%
2019 -3 100%
2020 -2 -100%
2021 -1 0%
2022 -1 0%
2023 -2 50%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Akeso, Inc. Free Cashflow
Year Free Cashflow Growth
2018 -197.571.000
2019 -113.885.750 -73.48%
2019 -355.868.000 68%
2020 -1.062.037.000 66.49%
2021 -1.713.364.000 38.01%
2022 -2.016.055.000 15.01%
2023 -774.393.000 -160.34%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Akeso, Inc. Operating Cashflow
Year Operating Cashflow Growth
2018 -123.417.000
2019 -54.898.750 -124.81%
2019 -219.595.000 75%
2020 -617.775.000 64.45%
2021 -1.001.238.000 38.3%
2022 -1.240.413.000 19.28%
2023 -403.468.000 -207.44%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Akeso, Inc. Capital Expenditure
Year Capital Expenditure Growth
2018 74.154.000
2019 58.987.000 -25.71%
2019 136.273.000 56.71%
2020 444.262.000 69.33%
2021 712.126.000 37.61%
2022 775.642.000 8.19%
2023 370.925.000 -109.11%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Akeso, Inc. Equity
Year Equity Growth
2018 488.095.000
2019 215.705.001 -126.28%
2020 3.450.438.999 93.75%
2021 3.280.266.000 -5.19%
2022 2.548.014.000 -28.74%
2023 4.518.777.000 43.61%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Akeso, Inc. Assets
Year Assets Growth
2018 651.718.000
2019 1.672.939.000 61.04%
2020 3.856.169.000 56.62%
2021 4.805.789.000 19.76%
2022 5.495.948.000 12.56%
2023 9.181.090.000 40.14%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Akeso, Inc. Liabilities
Year Liabilities Growth
2018 163.623.000
2019 1.457.234.000 88.77%
2020 405.730.000 -259.16%
2021 1.525.523.000 73.4%
2022 2.947.934.000 48.25%
2023 4.662.313.000 36.77%

Akeso, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
5.41
Net Income per Share
2.42
Price to Earning Ratio
25.6x
Price To Sales Ratio
11.84x
POCF Ratio
21.04
PFCF Ratio
30.66
Price to Book Ratio
11.06
EV to Sales
11.61
EV Over EBITDA
27.77
EV to Operating CashFlow
21.29
EV to FreeCashFlow
30.05
Earnings Yield
0.04
FreeCashFlow Yield
0.03
Market Cap
53,60 Bil.
Enterprise Value
52,55 Bil.
Graham Number
17.49
Graham NetNet
0.78

Income Statement Metrics

Net Income per Share
2.42
Income Quality
1.22
ROE
0.39
Return On Assets
0.22
Return On Capital Employed
0.22
Net Income per EBT
1.04
EBT Per Ebit
1.1
Ebit per Revenue
0.39
Effective Tax Rate
-0.02

Margins

Sales, General, & Administrative to Revenue
0.04
Research & Developement to Revenue
0.28
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.97
Operating Profit Margin
0.39
Pretax Profit Margin
0.43
Net Profit Margin
0.45

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
2.95
Free CashFlow per Share
2.09
Capex to Operating CashFlow
0.29
Capex to Revenue
0.16
Capex to Depreciation
5.12
Return on Invested Capital
0.23
Return on Tangible Assets
0.23
Days Sales Outstanding
23.83
Days Payables Outstanding
941.81
Days of Inventory on Hand
1040.13
Receivables Turnover
15.31
Payables Turnover
0.39
Inventory Turnover
0.35
Capex per Share
0.86

Balance Sheet

Cash per Share
5,85
Book Value per Share
5,40
Tangible Book Value per Share
5.02
Shareholders Equity per Share
5.61
Interest Debt per Share
3.57
Debt to Equity
0.64
Debt to Assets
0.33
Net Debt to EBITDA
-0.56
Current Ratio
4.71
Tangible Asset Value
4,20 Bil.
Net Current Asset Value
1,01 Bil.
Invested Capital
7656830000
Working Capital
4,47 Bil.
Intangibles to Total Assets
0.04
Average Receivables
0,30 Bil.
Average Payables
0,32 Bil.
Average Inventory
351127063.5
Debt to Market Cap
0.06

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Akeso, Inc. Dividends
Year Dividends Growth

Akeso, Inc. Profile

About Akeso, Inc.

Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes therapies. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) adenocarcinoma, hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), nasopharyngeal carcinoma (NPC), clear cell renal cell carcinoma, and solid tumors; and AK112, a PD-1/VEGF bi-specific antibody to treat solid and gynecological tumors, NSCLC, SCLC, and triple-negative breast cancer (TNBC). It is also developing AK105, a PD-1 monoclonal antibody to treat NSCLC, NPC, classic Hodgkin's lymphoma (R/R cHL), HCC, head and neck cancer, thyroid cancer, mesothelioma and thymic cancer, ESCC, UC, GC, GEJ, cholangiocarcinoma, neuroendocrine tumor, and mismatch repair deficient solid tumor; AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, GC, GEJ, ESCC, TNBC, HNSCC, R/R cHL, NPC, NSCLC, and solid tumors/lymphoma; AK119, a CD73 monoclonal antibody for treating solid tumors; and AK109, a VEGFR-2 monoclonal antibody to treat solid tumors and gastric cancer. In addition, the company develops AK120, an IL-4R monoclonal antibody to treat moderate-to-severe atopic dermatitis and asthma, and eosinophilic esophagitis; AK101, an IL-12/IL-23 monoclonal antibody to treat moderate-to-severe psoriasis and ulcerative colitis; AK111, an IL-17 monoclonal antibody to treat moderate-to-severe psoriasis and ankylosing spondylitis; and AK102, a PCSK9 monoclonal antibody to treat hypercholesterolemia. Further, its preclinical product includes AK127, a TIGIT monoclonal antibody to treat solid tumors; and AK115, a NGF monoclonal antibody. The company has collaboration agreements with Pfizer Pharmaceuticals, AstraZeneca Pharmaceuticals, and MD Anderson Medical Institute. Akeso, Inc. was founded in 2012 and is headquartered in Zhongshan, the People's Republic of China.

CEO
Dr. Yu Xia Ph.D.
Employee
2.815
Address
No. 6, Shennong Road
Zhongshan, 528437

Akeso, Inc. Executives & BODs

Akeso, Inc. Executives & BODs
# Name Age
1 Dr. Charlie Zhang Ph.D.
Senior Vice President
70
2 Dr. Xinfeng Zhang
Senior Vice President
70
3 Mr. Wenjun Shi
Senior Vice President
70
4 Dr. Peng Zhang Ph.D.
Co-Founder, Senior Vice President & Executive Director
70
5 Dr. Bing C. Wang M.B.A., Ph.D.
Chief Financial Officer
70
6 Dr. Yu Xia Ph.D.
Founder, Chief Executive Officer, President & Chairwoman
70
7 Dr. Baiyong Li Ph.D.
Co-Founder, Executive Vice President, CSO & Executive Director
70
8 Dr. Mingxiu Hu Ph.D.
Senior Vice President
70
9 Dr. Jing Min Ph.D.
Senior Vice President
70
10 Mr. Zhongmin Wang Ph.D.
Co-Founder, Senior Vice President & Executive Director
70

Akeso, Inc. Competitors

Innovent Biologics, Inc. Logo
Innovent Biologics, Inc.

1801.HK

(1.5)
InnoCare Pharma Limited Logo
InnoCare Pharma Limited

9969.HK

(1.0)
Peijia Medical Limited Logo
Peijia Medical Limited

9996.HK

(1.2)
BeiGene, Ltd. Logo
BeiGene, Ltd.

6160.HK

(0.5)
Alphamab Oncology Logo
Alphamab Oncology

9966.HK

(1.0)